Amendment: SEC Form 4 filed by Oep Vii Gp, L.L.C.

3/30/26 7:49:08 PM ET

$AHCO

Medical/Nursing Services

Health Care

Get the next $AHCO alert in real time by email

SEC FORM 4/ASEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

OEP VII GP, L.L.C.

(Last)

(First)

(Middle)

C/O ONE EQUITY PARTNERS

510 MADISON AVENUE, 19TH FLOOR

(Street)

NEW YORK

10022

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AdaptHealth Corp. [ AHCO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
03/23/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/19/2026		P		727	A	$9.9417⁽¹⁾	15,865,598	I	See⁽²⁾⁽³⁾
Common Stock	03/20/2026		P		447,100	A	$9.9121⁽⁴⁾	16,312,698	I	See⁽²⁾⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

1. Name and Address of Reporting Person^*

OEP VII GP, L.L.C.

(Last)

(First)

(Middle)

C/O ONE EQUITY PARTNERS

510 MADISON AVENUE, 19TH FLOOR

(Street)

NEW YORK

10022

(City)

(State)

(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

OEP AHCO Investment Holdings, LLC

(Last)

(First)

(Middle)

C/O ONE EQUITY PARTNERS

510 MADISON AVENUE, 19TH FLOOR

(Street)

NEW YORK

10022

(City)

(State)

(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

ONE EQUITY PARTNERS VII, L.P.

(Last)

(First)

(Middle)

C/O ONE EQUITY PARTNERS

510 MADISON AVENUE, 19TH FLOOR

(Street)

NEW YORK

10022

(City)

(State)

(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

ONE EQUITY PARTNERS VII-A, L.P.

(Last)

(First)

(Middle)

C/O ONE EQUITY PARTNERS

510 MADISON AVENUE, 19TH FLOOR

(Street)

NEW YORK

10022

(City)

(State)

(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

ONE EQUITY PARTNERS VII-B, L.P.

(Last)

(First)

(Middle)

C/O ONE EQUITY PARTNERS

510 MADISON AVENUE, 19TH FLOOR

(Street)

NEW YORK

10022

(City)

(State)

(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

OEP VII Project A Co-Investment Partners, L.P.

(Last)

(First)

(Middle)

C/O ONE EQUITY PARTNERS

510 MADISON AVENUE, 19TH FLOOR

(Street)

NEW YORK

10022

(City)

(State)

(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

OEP VII PROJECT A-I CO-INVESTMENT PARTNERS, L.P.

(Last)

(First)

(Middle)

C/O ONE EQUITY PARTNERS

510 MADISON AVENUE, 19TH FLOOR

(Street)

NEW YORK

10022

(City)

(State)

(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

OEP VII General Partner, L.P.

(Last)

(First)

(Middle)

C/O ONE EQUITY PARTNERS

510 MADISON AVENUE, 19TH FLOOR

(Street)

NEW YORK

10022

(City)

(State)

(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

CASHIN RICHARD M JR

(Last)

(First)

(Middle)

C/O ONE EQUITY PARTNERS

510 MADISON AVENUE, 19TH FLOOR

(Street)

NEW YORK

10022

(City)

(State)

(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.94 to $9.95, inclusive. The reporting persons undertake to provide to AdaptHealth Corp., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2. These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC").

3. (Continued from Footnote 2) The six member investment committee of OEP VII GP acts by majority vote, which majority must include Richard Cashin. Accordingly, Richard Cashin may be deemed to have voting and investment discretion, and beneficial ownership, of the reported securities. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.

4. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.81 to $9.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Remarks:

This filing is being amended solely to reflect Investor, the Parallel Funds, OEP VII GP, OEP VII GP LLC (collectively, the "OEP Entities") as reporting persons and direct and indirect holders of the reported securities, which were previously reported on a Form 4 that was timely filed by Richard Cashin on March 23, 2026 (the "Original Form 4 Filing"). As noted in the remarks, the Original Form 4 Filing disclosed the OEP Entities' direct and indirect ownership and noted that Edgar filing codes were not available at such time but that the Original Form 4 Filing would be amended once such codes became available.

	OEP VII GP, L.L.C., By: /s/ Gregory Belinfanti, Authorized Person	03/30/2026
	OEP AHCO INVESTMENT HOLDINGS, LLC, By: /s/ Gregory Belinfanti, Authorized Person	03/30/2026
	ONE EQUITY PARTNERS VII, L.P., By: OEP VII General Partner, L.P., its general partner, By: OEP VII GP, L.L.C., its general partner, By: /s/ Gregory Belinfanti, Authorized Person	03/30/2026
	ONE EQUITY PARTNERS VII-A, L.P., By: OEP VII General Partner, L.P., its general partner, By: OEP VII GP, L.L.C., its general partner, By: /s/ Gregory Belinfanti, Authorized Person	03/30/2026
	ONE EQUITY PARTNERS VII-B, L.P., By: OEP VII General Partner, L.P., its general partner, By: OEP VII GP, L.L.C., its general partner, By: /s/ Gregory Belinfanti, Authorized Person	03/30/2026
	OEP VII PROJECT A CO-INVESTMENT PARTNERS, L.P., By: OEP VII General Partner, L.P., its general partner, By: OEP VII GP, L.L.C., its general partner, By: /s/ Gregory Belinfanti, Authorized Person	03/30/2026
	OEP VII PROJECT A-I CO-INVESTMENT PARTNERS, L.P., By: OEP VII General Partner, L.P., its general partner, By: OEP VII GP, L.L.C., its general partner, By: /s/ Gregory Belinfanti, Authorized Person	03/30/2026
	OEP VII GENERAL PARTNER, L.P., By: OEP VII GP, L.L.C., its general partner, By: /s/ Gregory Belinfanti, Authorized Person	03/30/2026
	/s/ Richard Cashin	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Get the next $AHCO alert in real time by email

Recent Analyst Ratings for

$AHCO

Date	Price Target	Rating	Analyst
1/8/2024	$14.50 → $8.00	Buy → Hold	Jefferies
11/8/2023	$9.50 → $6.50	Neutral → Underperform	BofA Securities
5/10/2023	$28.00 → $11.30	Buy → Hold	Deutsche Bank
5/10/2023	$18.00 → $11.00	Buy → Hold	Stifel
5/9/2023	$21.00 → $12.00	Buy → Neutral	BofA Securities
3/8/2022	$31.00 → $26.00	Outperform	RBC Capital
3/2/2022	$32.00 → $24.00	Outperform	SVB Leerink
2/18/2022	$35.00 → $32.00	Outperform	SVB Leerink

More analyst ratings

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)

2. Transaction Date (Month/Day/Year)

2A. Deemed Execution Date, if any (Month/Day/Year)

3. Transaction Code (Instr. 8)

4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)

5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)

6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)

7. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

Amount

(A) or (D)

Price

Common Stock

03/19/2026

727

$9.9417⁽¹⁾

15,865,598

See⁽²⁾⁽³⁾

Common Stock

03/20/2026

447,100

$9.9121⁽⁴⁾

16,312,698

See⁽²⁾⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Recent Analyst Ratings for

$AHCO

Date	Price Target	Rating	Analyst
1/8/2024	$14.50 → $8.00	Buy → Hold	Jefferies
11/8/2023	$9.50 → $6.50	Neutral → Underperform	BofA Securities
5/10/2023	$28.00 → $11.30	Buy → Hold	Deutsche Bank
5/10/2023	$18.00 → $11.00	Buy → Hold	Stifel
5/9/2023	$21.00 → $12.00	Buy → Neutral	BofA Securities
3/8/2022	$31.00 → $26.00	Outperform	RBC Capital
3/2/2022	$32.00 → $24.00	Outperform	SVB Leerink
2/18/2022	$35.00 → $32.00	Outperform	SVB Leerink

More analyst ratings

Amendment: SEC Form 4 filed by Oep Vii Gp, L.L.C.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$AHCO

Amendment: SEC Form 4 filed by Oep Vii Gp, L.L.C.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$AHCO

$AHCO
SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by AdaptHealth Corp.

Amendment: SEC Form SCHEDULE 13D/A filed by AdaptHealth Corp.

SEC Form 10-K filed by AdaptHealth Corp.

$AHCO
Insider Purchases

Large owner Cashin Richard M Jr bought $19,912,148 worth of shares (2,046,691 units at $9.73) (SEC Form 4)

Director Wolf Dale B bought $71,680 worth of shares (8,000 units at $8.96), increasing direct ownership by 8% to 104,235 units (SEC Form 4)

CLO and General Counsel Rew Richard W. Ii bought $44,550 worth of shares (5,000 units at $8.91), increasing direct ownership by 5% to 107,097 units (SEC Form 4)

$AHCO
Press Releases

AdaptHealth Corp. to Participate in Upcoming Investor Conferences

AdaptHealth Corp. Announces Fourth Quarter and Full-Year 2025 Results and Provides 2026 Financial Guidance

AdaptHealth Corp. Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call

$AHCO
Insider Trading